Cargando…
Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia
Objective: To explore the treatment response, tolerability and safety of once-monthly paliperidone palmitate (PP1M) in non-acute patients switched from oral antipsychotics, stratified by time since diagnosis as recently diagnosed (≤3 years) or chronic patients (>3 years). Research design and meth...
Autores principales: | Hargarter, L, Bergmans, P, Cherubin, P, Keim, S, Conca, A, Serrano-Blanco, A, Bitter, I, Bilanakis, N, Schreiner, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898156/ https://www.ncbi.nlm.nih.gov/pubmed/27042990 http://dx.doi.org/10.1080/14656566.2016.1174692 |
Ejemplares similares
-
PM480. Early schizophrenia patients treated with once-monthly paliperidone palmitate over a 12-month period - A Retrospective Observational Study
por: Schreiner, Andreas, et al.
Publicado: (2016) -
Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
por: Emsley, Robin, et al.
Publicado: (2017) -
PM479. Clinical and Functional Response to Paliperidone Palmitate in Early Schizophrenia – A Retrospective Observational Study in Newly Diagnosed Patients Treated Over a 12-Month Period
por: Schreiner, Andreas, et al.
Publicado: (2016) -
Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study
por: Schreiner, Andreas, et al.
Publicado: (2016) -
PM481. Tolerability, safety and treatment response of flexibly-dosed paliperidone palmitate in patients hospitalized for an exacerbation of schizophrenia
por: Schreiner, Andreas, et al.
Publicado: (2016)